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Abstract
Background: Radioactive iodine is commonly administered following thyroidectomy for differentiated thyroid carcinoma to
ablate the thyroid remnant. The optimal administered activity of radioiodine is unknown.
Methodology/Principal Findings: Adult subjects (n=160) diagnosed with papillary or follicular thyroid carcinoma were
randomly allocated to receive either 1100 MBq (30 mCi) or 3700 MBq (100 mCi) activity of radioiodine (
131I) following
thyroidectomy. The study participants were prepared for ablation using thyroid hormone withdrawal. Ablation was
considered successful when serum thyroglobulin concentration was less than 1 ng/mL and no uptake was present in
131I
scan. Ablation was successful following one administration of radioiodine in 42 (52%; 95% CI, 41% to 63%) of the 81
evaluable study participants who received 1100 MBq, and in 43 (56%, 45% to 67%) of the 77 subjects who received 3700
MBq activity (P=.61). There was no difference between the groups in the numbers of repeat radioiodine treatments needed
to complete ablation (P=.27). The higher activity was associated with more nausea and taste disturbances, and a longer
stay in a radioprotected isolation unit. None of the participants died from thyroid cancer during a median follow up of 51
months; three subjects in the 3700 MBq group and none in the 1100 MBq group were diagnosed with distant metastases
during follow-up. In a meta-analysis of four randomized studies that compared the 1100 and 3700 MBq activities, the 1100
MBq activity tended to be associated with a higher risk of unsuccessful ablation (relative risk 1.148, 95% CI 0.974 to 1.353,
P= .10).
Conclusions/Significance: The results provide no conclusive evidence that 3700 MBq activity is more effective for ablation
of the thyroid remnant than 1100 MBq activity. The 3700 MBq activity is associated with more adverse effects.
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Introduction
Radioiodine ablation is recommended for most patients
diagnosed with papillary or follicular thyroid carcinoma following
thyroidectomy [1]. The potential advantages include eradication
of occult carcinoma foci, and improved sensitivity of postoperative
131I scanning and serum thyroglobulin measurements for detection
of recurrent disease [2]. Ablation is generally well tolerated, but
may be associated with transient neck pain and oedema,
sialadenitis, lethargy, impairment of gonadal functions, and
rarely radiation-associated second cancer [2,3]. Its efficacy in
prevention of cancer recurrence has never been compared to
surgery alone in a randomized trial, but some uncontrolled studies
suggest that ablation may reduce substantially the risk of cancer
recurrence [4].
The administered iodine activity needed to ablate the thyroid is
controversial. The administered activities vary widely between
centers from as small as 925 MBq (25 mCi) to as high as 7400
MBq (200 mCi) regardless of whether chosen empirically or based
on dosimetry-guided techniques [2,5]. Retrospective cohort studies
[4] and randomized studies [6–10] suggest that low activities
within the range of 1100 MBq (30 mCi) to 1850 MBq (50 mCi)
might be as effective as higher activities, but the few randomized
studies performed have been criticized for their small patient
numbers and inadequate methodology [5], and the uncontrolled
cohort studies may contain inherent biases. The relative benefits
and harms of lower and higher administered activities thus remain
unknown.
We evaluated the safety and efficacy of two commonly used
radioiodine ablative activities (1100 MBq, 30 mCi; and 3700
MBq, 100 mCi) administered following thyroidectomy for
differentiated thyroid cancer. We made an effort to accrue
the majority of patients who underwent total or near total
thyroidectomy in a single center. Since efficacy of
131I depends on
the amount of the thyroid tissue left behind at surgery, we
restricted the study within a patient population treated with
thyroidectomy. To our knowledge, this is the first randomized
study on thyroid ablation that addresses also adverse effects
of radioiodine and duration of isolation required following
administration.
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The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Study population
One-hundred and sixty patients with histologically confirmed
thyroid carcinoma were entered to this prospective, randomized,
phase III, open-label, single-center study between January 2000
and October 2004. Patients were required to have undergone
either total or near total thyroidectomy, have either papillary or
follicular thyroid carcinoma diagnosed according to the World
Health Organization (WHO) criteria [11], and they were expected
to tolerate radioiodine administration. Patients who presented with
macroscopic inoperable locoregional disease or with distant
metastases were excluded, as well as pregnant women. The study
participants are consecutive with the exception of the patients who
were not eligible, those who selected not to participate, and a few
patients who were not included because of logistic reasons
(Figure 1). Staging work-up was performed four to five weeks
after thyroidectomy and included physical examination, blood cell
counts, blood biochemistry, serum thyroglobulin and triiodothy-
ronine measurements, and usually chest X-ray. Postoperative neck
ultrasonography or computed tomography were not mandated by
the protocol.
All participants were randomly allocated to receive either 1110
or 3700 MBq activity of
131I five to six weeks after thyroidectomy.
At randomization, patients were stratified according to the
presence or absence of histologically verified cervical lymph node
metastases. Randomization was carried out centrally, and was
done with a computer program where random digits were
weighted based on the proportion of past randomizations to yield
a balanced number of randomizations between the two groups in a
concealed fashion.
The primary endpoint was successful thyroid ablation defined as
1) absence of abnormal uptake in a diagnostic whole body
131I
scan, 2) undetectable (less than 1 ng/mL) serum thyroglobulin
during both levothyroxine administration and thyroid
stimulating hormone (TSH) stimulation, and 3) absence of
palpable metastases in the neck. All three conditions had to be
met for ablation to be considered as successful. We performed a
second efficacy analysis (not specified by the study protocol) taking
absence of abnormal activity in a diagnostic radioiodine scan as
the sole criterion for successful ablation. Other endpoints in the
study were tolerability of radioiodine treatment, the number of
subsequent radioiodine treatments required to complete thyroid
ablation, absorbed activity in the neck following
131I administra-
tion, and the time spent in an isolation unit following radioiodine
administration.
All patients signed an informed consent prior to performing any
of the study procedures. The study was approved by an ethics
committee of Helsinki University Central Hospital, and conducted
according to the guidelines of the Declaration of Helsinki. This
trial was registered with an identifier NCT00115895 at www.
clinicaltrials.gov.
Study procedures
Thyroid stimulating hormone (TSH) stimulation was achieved
by abstaining from levothyroxine administration for a minimum of
four weeks prior to radioiodine administration. A diet containing
low iodine content was recommended prior to ablation. The
median serum TSH concentration was 69.0 mU/L (range, from 6
to 1180 mU/mL) when measured 0 to 14 days prior to
131I
administration (in the 1100 MBq group the median was 67.5 mU/
L, range, from 18 to 1180 mU/L; in the 3700 MBq group the
median was 71 mU/L, range, from 6 to 242 mU/L; P=.55); 146
(91%) patients had TSH 30 mU/L or higher.
A small
131I activity (7.4 MBq, 0.2 mCi) was administered orally
four to five weeks after thyroidectomy to measure radioiodine
accumulation in the thyroid bed. The percentage uptake was
measured with an Atomlab 950 Thyroid Uptake System (Biodex,
New York, USA) 48 hours after administration of 7.4 MBq
radioiodine. The ablative radioiodine activity (1100 MBq or 3700
MBq) was administered approximately five days later as oral
capsules that were swallowed with water.
Figure 1. A consort diagram of the study.
doi:10.1371/journal.pone.0001885.g001
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administration until the radiation protection limit required by the
Finnish authorities was met; the remaining whole body
131I
activity was required to be less than 400 MBq corresponding to
approximately 15 mSv/h dose equivalent rate measured with a
Geiger counter at one meter distance. Oral levothyroxine
replacement therapy was initiated four days after radioiodine
administration and adjusted individually based on serum TSH and
free triiodothyronine measurements.
A whole-body iodine scan and single-photon emission comput-
ed tomography (SPECT) were performed four to seven days after
ablative
131I administration using a double-headed Toshiba 7200
A/UI gamma camera (Toshiba Medical Systems, Nasu, Japan)
equipped with high energy parallel-hole collimators. SPECT was
done in 139 (87%) cases; it was not performed in 21 cases due to
logistic reasons. The effective radioiodine activity half-life (TK)eff
in the neck was calculated using the physical (TKphys, eight days)
and biological (TKbiol) half-lives. The absorbed radiation dose to
the thyroid bed was calculated in 121 (76%) cases [12].
The success of ablation was assessed four to eight months after
131I administration. Serum thyroglobulin levels were measured
both while the patient was receiving levothyroxine and during
TSH stimulation, which was achieved by abstaining from
levothyroxine administration or by administering recombinant
human TSH (rhTSH) for patients judged to tolerate abstaining
from levothyroxine poorly (n=11; four in the low activity arm and
seven in the high activity arm). Serum thyroglobulin was analyzed
using immunofluorometry (normal reference range, ,24 ng/mL).
In addition, a diagnostic whole body scan, carried out under TSH
stimulation, was performed after administration of 185 MBq of
131I. It was not performed when serum thyroglobulin
was detectable ($1 ng/mL) while the patient was receiving
levothyroxine.
Radioiodine ablation was repeated whenever serum thyroglob-
ulin was detectable or when abnormal uptake was present in the
thyroid bed or at extrathyroid sites in a diagnostic radioiodine
scan. The repeat administered activity was the same as the first
administered activity except for 15 patients in the 1100 MBq
group who received 3700 MBq and for one patient in the 3700
MBq group who received 2960 MBq. When a second repeat
treatment was required, all but two patients received at least 3700
MBq.
Adverse effects related to radioiodine administration, graded
according to the National Cancer Institute Common Toxicity
Criteria version 2.0, were recorded by the study participants on
structured forms approximately four days before
131I administra-
tion, and four to seven days, two to three weeks, and three months
following treatment.
Statistical methods
We estimated that one radioiodine treatment would be
successful in 40% of the study participants allocated to the 1100
MBq group and in 60% of those allocated to the 3700 MBq group.
Using power (1-b) 80%, a .05 and a one-sided test, 160
participants were to be recruited to the study. An interim safety
analysis was carried out when 80 patients had been evaluated for
efficacy; a stopping rule was to be applied if a 50% difference in
the success rate was observed in favor of the higher administered
activity group.
Analyses were done according to the intention-to-treat principle
with superiority approach. Frequency tables were analysed with
the chi-square test or Fisher’s exact test. The Bonferroni method
was used to correct for multiple testing. Distributions of the days
spent in an isolation unit were compared using the Mann-Whitney
test. Confidence intervals for one proportion were calculated using
normal approximation. A formal meta-analysis was conducted
using pooled data from three previous studies and the present
study. The combined relative risk (RR) and the 95% confidence
interval for the RR were estimated with a fixed effect assumption.
The heterogeneity between the studies was evaluated using
Cochran’s test. All P values are two-tailed. Statistical analyses
carried out using an SASH version 8.2 for Windows (SAS Institute
Inc., Cary, NC, USA).
Results
Patients
Eighty-one patients received 1110 MBq of
131I and 79 received
3700 MBq as the ablative activity (Figure 1). Radioiodine was
administered a median of 38 days after thyroidectomy (range, 27
to 124 days; 93% received treatment within six weeks from
surgery).
All entered patients were eligible. Two patients in the 3700
MBq group could not be evaluated for completeness of thyroid
ablation; one refused evaluation and another one died of acute
myeloid leukaemia three months after radioiodine administration.
Randomization was balanced (Table 1). Three patients in the
1110 MBq group and one in the 3700 MBq group had no
131I
uptake in the neck with undetectable serum thyroglobulin
following thyroidectomy; none had
131I uptake comparable to an
intact thyroid. Two patients allocated to the 3700 MBq group
received only 2220 MBq due to a high radioiodine uptake in the
thyroid bed after administration of a 7.4 MBq test dose (14.6%
and 18.5% of the administered activity accumulated in the thyroid
bed in these two cases).
Treatment
Ablation was successful in 42 (52%; 95% CI, 41% to 63%) of
the 81 evaluable patients who received 1100 MBq and in 43 (56%;
95% CI, 45% to 67%) of those who received 3700 MBq (P= .61,
Table 2).
When an exploratory analysis was carried out using absence of
abnormal activity in a diagnostic radioiodine scan as the sole
criterion of successful ablation, a slightly larger proportion of the
patients treated with the higher administered activity tended to
become successfully ablated (76%; 95% CI, 67% to 86% vs. 64%;
95% CI, 53% to 74%; P =.09).
There was no significant difference in efficacy between the
administered radioiodine activities in any of the post hoc subgroup
analyses performed (male vs. female; age ,45 vs. $45; papillary
vs. follicular cancer; tumor diameter ,4 cm vs. $4 cm; cervical
nodal status negative, pN0 vs. positive, pN+; serum pretreatment
thyroglobulin ,10 ng/mL vs. $10 ng/mL; ,20 ng/mL vs.
$20 ng/mL; and neck
131I uptake ,2% vs. $2 %). Of note, a
single radioiodine treatment was unsuccessful in all 18 patients
who had serum thyroglobulin 20 ng/mL or higher at baseline
regardless of the activity administered, whereas it was successful in
83 (61%) of those patients who had a serum thyroglobulin
concentration lower than 20 ng/mL (P ,.0001). Similarly, using a
cut-off value of 10 ng/mL for serum thyroglobulin, only six (19%)
of the 32 first radioiodine ablation treatments were successful
among the patients who had a serum thyroglobulin level 10 ng/
mL or higher prior to radioiodine treatment as compared to 77
(63%) of those who had a lower level (P ,.0001). Only two (17%)
of the 12 patients who had cervical nodal metastases (pN+) had
successful ablation following the first radioiodine administration as
compared to 83 (57%) of the 146 patients who had no cervical
metastases (pN0, P =.029), and 7 (32%) of the 22 patients with a
Radioiodine for Ablation
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ablation as compared to 76 (58%) of the 132 patients who had a
smaller primary tumor at diagnosis (P =.10).
Repeat treatments
There was no difference between the groups in the numbers of
repeat treatments needed to complete ablation. Thirty-eight (47%)
patients allocated to the 1100 MBq group had one or more repeat
treatments (27 had one, 11 had two or more repeat treatments) as
compared to 32 (42%) patients allocated to the 3700 MBq group
(22 had one, and ten had two or more repeat treatments; P =.41).
Three patients did not receive a repeat treatment despite
incomplete ablation (1100 MBq group, one; 3700 MBq group,
two).
Adverse effects
Radioiodine was generally well tolerated, and the frequency of
adverse effects decreased with time. All adverse effects were mild
(grade 1 or 2) except for nausea, which was severe in four (6%)
patients allocated to the 1100 MBq group and in seven (10%) in
the 3700 MBq group (P =.33). Patients who received a lower
activity had less nausea and taste disturbances, and tended to have
less pain in the salivary glands (Table 3). Ten patients (13%) in the
3700 MBq group and four (5%) in the 1100 MBq group required
medication for neck pain (P =.082).
Duration of stay in an isolation unit
A higher administered activity was associated with a longer stay
in an isolation unit (Table 4). The median duration of stay was two











Female 65 (80) 63 (80)




Not available 3 1
Histology
Papillary 74 (91) 72 (91)
Follicular 4 ( 5) 7 ( 9)
Both papillary and follicular 3 ( 4) 0 ( 0)
Cervical lymph node metastases
Present (pN0) 5 ( 6) 7 ( 9)
Not present (pN+) 7 6( 9 4 ) 7 2( 9 1 )
Multifocal cancer
Yes 25 (31) 29 (37)
No 56 (69) 50 (63)
No. of lobes affected
One 64 (79) 59 (75)
Both 17 (21) 20 (25)
Serum thyroglobulin prior to radioiodine treatment
,1 ng/mL 28 (35) 29 (37)
$1 ng/mL 53 (65) 47 (59)
Not available 0 ( 0) 3 ( 4)
131I uptake in an isotope scan
No uptake 5 ( 6) 3 (4)
Uptake 76 (94) 74 (94)
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activity group and three days (range, from two to six days) in the
3700 MBq group (P ,.0001).
Absorbed dose
We calculated a mean absorbed dose of 26 Gy (range, 1 to 224
Gy) in the thyroid bed in the 1110 MBq group and 76 Gy (range, 1
to 675 Gy) in the 3700 MBq group, but these figures are unlikely
to be accurate, since the small size of the thyroid remnants
together with the partial volume effect in scintigraphy prohibited
reliable estimation of the volumes smaller than 3–4 cm
3 in size,
which was the case in the majority of cases. The measured mean
absorbed dose per one MBq of administered
131I activity in the
thyroid bed was similar between the allocation groups. We found
no correlation between the success of ablation and the calculated
absorbed dose.
Cancer recurrence
The median follow-up time was 51 months from the date of
randomization (range, from 18 to 77 months). Metastastic cervical
lymph nodes were removed from 12 patients (the 1100 MBq group,
n=6; the 3700 MBq group, n=6; P=.52). Sixty-eight (84%)
patients allocated to receive 1100 MBq
131I were alive with
undetectable serum thyroglobulin and with no abnormal uptake in
a radioiodine scan at the end of follow-up as compared to 65 (82%)
among those who received 3700 MBq. Three patients in the 3700
MBq group and none in the 1100 MBq group were diagnosed with
distant metastases (P=.12, Fisher’s exact test). None died from
thyroid cancer during follow-up; three patients died of a competing
cause (1100 MBq group, two; 3700 MBq group, one).
Meta-analysis of published trials
To the best of our knowledge, the studies listed in Table 5 are
the only ones that have compared the 1100 MBq and 3700 MBq
radioiodine activities in randomized prospective trials [13]. There
was no significant heterogeneity between the four studies (P=.71,
Cochran’s test). The success rate for thyroid remnant ablation was
71.3% with the 3700 MBq activity and 62.1% with the 1100 MBq
activity in a meta-analysis of the four studies. The relative risk
(RR) for unsuccessful thyroid remnant ablation tended to be
greater after administration of the smaller activity (RR 1.148, 95%
confidence interval 0.974 to 1.353, P=.10; Figure 2).
Discussion
We found no conclusive evidence that the higher radioiodine
activity (3700 MBq) is more often associated with successful
thyroid remnant ablation than the smaller activity (1100 MBq)
when administered following thyroidectomy. In general, the
smaller administered radioiodine activity was better tolerated.
Six prior randomized studies have evaluated radioiodine activity in
thyroid ablation [6–10,14]. Five of these studies were small and
included 20 to 138 patients each [6–9,14]. The only large trial
accrued 509 patients diagnosed with papillary or follicular thyroid
cancer in Northern India [10]. In this study the participants were
divided into eight groups treated with different activities ranging
from 555 MBq (15 mCi) to 1850 MBq (50 mCi). A higher success
rate (81.6%) was reported with activities of 925 MBq or greater as
compared to lower activities (555 or 740 MBq, 61.8%). However,
Table 3. Recorded Common Adverse Effects Related to
Radioiodine Treatment
Adverse effect Radioiodine activity administered P







3 11/68 (17) 24/67 (37) .0092
2 weeks 5/63 ( 8) 10/59 (18) .13
3 months 1/64 ( 2) 2/57 ( 4) .60
Pain in the neck
5 days 21/68 (30) 26/67 (40) .33
2 weeks 18/63 (29) 16/59 (27) .86
3 months 7/64 (12) 10/57 (27) .35
Pain in salivary glands
5 days 10/68 (15) 18/67 (26) .08
2 weeks 7/63 (12) 10/59 (16) .35
3 months 1/64 ( 2) 2/57 ( 4) .60
Altered taste
5 days 12/68 (18) 10/67 (15) .67
2 weeks 9/63 (14) 17/59 (28) .050
3 months 0/64 ( 0) 4/57 ( 6) .047
Altered smell
5 days 5/68 ( 7) 6/67 ( 9) .73
2 weeks 5/63 ( 8) 3/59 ( 5) .72
3 months 0/64 ( 0) 0/57 ( 2) 1.00
Dry eyes
5 days 5/68 ( 7) 10/67 (15) .16
2 weeks 4/63 ( 6) 7/59 (13) .29
3 months 5/64 ( 8) 8/57 (15) .27
Dry mouth
5 days 8/68 (13) 15/67 (21) .10
2 weeks 4/63 ( 6) 4/59 ( 7) 1.00
3 months 4/64 ( 6) 3/57 ( 5) 1.00
1number of patients with reported adverse effects (n) of the number of
evaluable patients (N)
2nausea was graded severe (gr. 3) in four and seven cases in the 1100 and 3700
MBq groups, respectively
3time from radioiodine treatment administration to evaluation
doi:10.1371/journal.pone.0001885.t003








Thyroglobulin ,1 ng/mL, and
Thyroglobulin ,1 ng/mL, and no





No uptake in a diagnostic
radioiodine scan
3
49/77 (64) 55/72 (76) .09
1number of successful treatments (n) of the number of evaluable patients (N)
2one patient selected not to be evaluated, one died of acute myeloid leukemia
3diagnostic radioiodine scan was not performed in four cases in the 1100 MBq
group and in five cases in the 3700 MBq group, since serum thyreoglobin was
detectable while the patient received levothyroxine supplementation
doi:10.1371/journal.pone.0001885.t002
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underwent subtotal thyroidectomy or hemithyroidectomy, post-
operative neck radioiodine uptake was generally high, the timing
of ablation ranged between one month and nine years after
surgery, a single primary end-point was not used, and 18% fewer
patients than expected were allocated to the two groups that
received the least activity.
Three prior randomized trials have compared the 1100 MBq
activity with the 3700 MBq activity [6–8]. Although these studies
have been criticized for their small size and methodology [5], the
results are in line with the present findings (Table 5). The results of
the meta-analysis performed by us found that the success rate in
thyroid remnant ablation as evaluated by radioiodine scan tends to
be higher with the 3700 MBq activity than with the 1100 MBq
activity. The relative risk of unsuccessful ablation was 1.148 with the
1100 MBq activity, but the 95% confidence interval crossed 1.0 and
the difference was thus not statistically significant. When the data of
the meta-analysis(RR1.148,successrates71.3%vs.62.1%)areused
todesign a study aiming todemonstratesuperiorityof the 3700 MBq
radioiodine activity over the 1100 MBq activity using a two-sided
significance level of 0.05 and power of 80%, altogether 822 subjects
would need to be entered to the study. The number of study
participants required may be even larger than this when successful
ablation is defined by undetectable serum thyroglobulin concentra-
tion and a negative radioiodine scan. All studies performed so far
may thus have been inadequately powered to be able to reliably
demonstratea differenceinsuccess ofthyroid ablation between these
two radioiodine activities.
Three randomized trials have compared 1100 MBq (30 mCi)
activity with 1800 MBq (50 mCi) activity,
8,10,14 and two
randomized trials 1800 MBq activity with 3700 MBq (100 mCi)
activity.
8,9 Although some trials suggest that a high activity is more
efficacious,
9,14 the pooled risk ratios are not statistically significant
and the results are therefore consistent with there being a superior
effect associated with a high activity or no difference (reviewed in
Hackshaw et al.
13).
Table 4. Duration of Stay in an Isolation Unit
Number of days spent
in an isolation unit Radioiodine activity administered P
1110 MBq 3700 MBq
n( % ) n( % )
2 47 (58) 2 ( 3) ,.0001
3 29 (36) 41 (52)
4 5 ( 6) 32 (41)
5 0(0 ) 3(4 )
6 0(0 ) 1(1 )
doi:10.1371/journal.pone.0001885.t004
Figure 2. Meta-analysis of success of ablation in randomized prospective trials that have compared the 1100 MBq and 3700 MBq
activities in ablation of the thyroid remnant. Relative risk (RR) with 95% confidence interval is shown. RR greater than 1.0 favors high activity
treatment.
doi:10.1371/journal.pone.0001885.g002
Table 5. Reported Ablation Success Rates by Radioiodine
Activity in Randomized Studies Comparing Low (1100 MBq)
and High (3700 MBq) Administered Activity
Study
Proportion of patients successfully treated
1
by activity




Creutzig et al. (1987) 50 (5/10) 60 (6/10)
Johansen et al. (1991) 58 (21/36) 52 (14/27)
Bal et al. (1996) 63 (17/27) 74 (28/38)
Present study 64 (49/77) 76 (55/72)
Total 61 (92/150) 70 (103/147)
1assessed as absence of abnormal activity in radioiodine scan
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node-negative, and no extension beyond the thyroid capsule have
low long-term recurrence rate (,2%) and may not benefit from
adjuvant radioiodine, whereas radioiodine is likely beneficial when
carcinoma persists in the neck or elsewhere. Selective use of
radioiodine may be recommended for patients who have disease
between these two extremes [15]. The American Thyroid Cancer
Association Guidelines Taskforce recommends radioiodine abla-
tion for stage III and IV disease (defined as American Joint
Committee on Cancer 6
th edition), to all patients with stage II
disease younger than age 45 years and most patients with stage II
disease 45 years or older, and to selected patients with stage I
disease [1].
The National Compehensive Cancer Network (NCCN) guide-
lines recommend use of 30 to 100 mCi radioiodine in cases of
papillary, follicular or Hrthle cell carcinoma $1 cm in diameter,
with nodal or distant metastases, or with aggressive histology when
there is suspected or proven thyroid bed uptake in total body
radioiodine scan after thyroidectomy [16].
Higher administered activity was associated with more nausea
and taste disturbances. The absolute risk for radioiodine-induced
cancers has not been well established, but the risk of any second
primary cancer after initial diagnosis of thyroid cancer is increased
approximately 30% over that of the general population [17,18],
and the risk appears to increase with increasing cumulative
administered activity [18]. Radioiodine treatment may be
associated with transient hypospermia and amenorrhea; perma-
nent gonadal damage has been observed with cumulative activities
exceeding 18.5–22.2 GBq [19,20].
Only three patients developed distant metastases during the
follow-up. This finding suggests that if the time to distant
recurrence or overall survival are selected as the study primary
endpoints, the study size needs to be very large, and it is doubtful
whether such a study will be conducted. However, studies larger
than the present one addressing radioiodine activity are warranted
to exclude small but still clinically significant differences in efficacy
between small and high administered radioiodine activities. The
present study was a single-center trial, which is a limitation of the
study, and further studies addressing radioiodine activity should
preferentially be carried out in a multicenter setting. We used
serum thyroglobulin levels as the basis of evaluation of success of
radioiodine ablation, because whole body
131I scanning generally
has low sensitivity after radioiodine ablation [15,21,22].
In conclusion, the results of the present trial and the meta-
analysis provided no conclusive evidence that administration of
3700 MBq activity is more effective for ablation of the thyroid
remnant than 1100 MBq activity among patients treated with total
thyroidectomy for differentiated thyroid carcinoma. Administra-
tion of the smaller activity is associated with fewer common
adverse effects and a shorter stay in a radiation protection unit,
and does not result in more repeat treatments. The relative
benefits and harms of using high (3700 MBq) as compared to low
(1100 MBq) radioiodine activity remain inadequately studied,
since none of the prior studies have addressed important aspects in
clinical decision-making such as side effects of radioiodine
administration, duration of isolation, or cancer recurrence rates
after radioiodine administration.
6,7,8 Evidence for selection of one
or the other of the two radioiodine activities thus remains
inconclusive. Importantly, the anti-cancer efficacy of different
radioiodine activities has not been addressed in large, adequately
powered controlled clinical trials. Such trials should receive a high
priority.
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